Citadel Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Citadel Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,641,884	Closed	-$3.96M	–	12868
2025 Q4	$3.96M	Buy	1,641,884 +100,558	+7%	+$219K	﹤0.01%	4675
2025 Q3	$2.79M	Sell	1,541,326 -354,193	-19%	-$498K	﹤0.01%	5434
2025 Q2	$2.26M	Hold	1,895,519	–	–	﹤0.01%	5481
2025 Q1	$3.85M	Sell	1,895,519 -224,127	-11%	-$1.21M	﹤0.01%	4320
2024 Q4	$12.8M	Sell	2,119,646 -20,982	-1%	-$152K	﹤0.01%	2662
2024 Q3	$15M	Buy	2,140,628 +20,982	+1%	+$165K	﹤0.01%	2380
2024 Q2	$12.3M	Buy	2,119,646 +439,619	+26%	+$3.54M	﹤0.01%	2519
2024 Q1	$12M	Buy	1,680,027 +30,368	+2%	+$141K	﹤0.01%	2691
2023 Q4	$8.12M	Sell	1,649,659 -798	-0%	-$4.21K	﹤0.01%	3122
2023 Q3	$15.8M	Buy	1,650,457 +811	+0%	+$9.37K	﹤0.01%	2135
2023 Q2	$21.4M	Buy	1,649,646 +8,624	+0.5%	+$104K	﹤0.01%	1816
2023 Q1	$20.1M	Buy	1,641,022 +6,918	+0.4%	+$116K	﹤0.01%	1906
2022 Q4	$18.2M	Buy	+1,634,104	New	+$20.7M	﹤0.01%	2065

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's ACRV Position: Q1 2026 in Review

Citadel Advisors sold out of Acrivon Therapeutics (ACRV) in Q1 2026, closing a stake of 1,641,884 shares — an estimated $3.96M sold.

Citadel Advisors first reported a position in ACRV in Q4 2022 and held it in 13 quarters. The position peaked at $21.4M in Q2 2023. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Citadel Advisors reported no remaining Acrivon Therapeutics position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 1,641,884 Acrivon Therapeutics shares in Q1 2026, an estimated $3.96M.
Citadel Advisors first reported a position in Acrivon Therapeutics in Q4 2022 and held it in 13 quarters.
Citadel Advisors's Acrivon Therapeutics position peaked at $21.4M in Q2 2023.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.